share_log

Goldman Sachs Maintains Sell on FibroGen, Raises Price Target to $16

Benzinga ·  Feb 23, 2023 20:50

Goldman Sachs analyst Paul Choi maintains FibroGen (NASDAQ:FGEN) with a Sell and raises the price target from $9 to $16.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment